Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Sumitomo Dainippon Pharma Co ( (JP:4506) ) is now available.
Sumitomo Pharma Co., Ltd. has finalized the sale of 60% of its newly established subsidiary, SMP Jumbi Kabushikigaisya, to Marubeni Global Pharma Corporation as part of a strategic restructuring of its Asian business. This transaction resulted in a gain of approximately 49.043 billion yen, which has been incorporated into the company’s financial results, potentially impacting its market positioning and financial forecasts.
The most recent analyst rating on (JP:4506) stock is a Buy with a Yen2100.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd. is a pharmaceutical company based in Osaka, Japan, focusing on the manufacturing and sales of pharmaceuticals. It operates in the healthcare industry, providing products and services primarily in the Asian market.
Average Trading Volume: 6,926,226
Technical Sentiment Signal: Buy
Current Market Cap: Yen679.4B
See more insights into 4506 stock on TipRanks’ Stock Analysis page.